Abstract

Here, we assessed whether 41 SNPs within steroid hormone genes associated with erosive disease. The most relevant finding was the rheumatoid factor (RF)-specific effect of the CYP1B1, CYP2C9, ESR2, FcγR3A, and SHBG SNPs to modulate the risk of bone erosions (P = 0.004, 0.0007, 0.0002, 0.013 and 0.015) that was confirmed through meta-analysis of our data with those from the DREAM registry (P = 0.000081, 0.0022, 0.00074, 0.0067 and 0.0087, respectively). Mechanistically, we also found a gender-specific correlation of the CYP2C9rs1799853T/T genotype with serum vitamin D3 levels (P = 0.00085) and a modest effect on IL1β levels after stimulation of PBMCs or blood with LPS and PHA (P = 0.0057 and P = 0.0058). An overall haplotype analysis also showed an association of 3 ESR1 haplotypes with a reduced risk of erosive arthritis (P = 0.009, P = 0.002, and P = 0.002). Furthermore, we observed that the ESR2, ESR1 and FcγR3A SNPs influenced the immune response after stimulation of PBMCs or macrophages with LPS or Pam3Cys (P = 0.002, 0.0008, 0.0011 and 1.97•10−7). Finally, we found that a model built with steroid hormone-related SNPs significantly improved the prediction of erosive disease in seropositive patients (PRF+ = 2.46•10−8) whereas no prediction was detected in seronegative patients (PRF− = 0.36). Although the predictive ability of the model was substantially lower in the replication population (PRF+ = 0.014), we could confirm that CYP1B1 and CYP2C9 SNPs help to predict erosive disease in seropositive patients. These results are the first to suggest a RF-specific association of steroid hormone-related polymorphisms with erosive disease.

Details

Title
Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium
Author
Sánchez-Maldonado, Jose M 1 ; Cáliz, Rafael 2 ; Canet, Luz 3 ; Rob ter Horst 4   VIAFID ORCID Logo  ; Bakker, Olivier 5 ; den Broeder, Alfons A 6 ; Martínez-Bueno, Manuel 7 ; Canhão, Helena 8 ; Rodríguez-Ramos, Ana 3   VIAFID ORCID Logo  ; Lupiañez, Carmen B 3 ; Soto-Pino, María José 9 ; García, Antonio 9 ; Pérez-Pampin, Eva 10 ; González-Utrilla, Alfonso 9 ; Escudero, Alejandro 11 ; Segura-Catena, Juana 3 ; Netea-Maier, Romana T 4 ; Ferrer, Miguel Ángel 9 ; Collantes-Estevez, Eduardo 11 ; López Nevot, Miguel Ángel 12 ; Yang, Li 5 ; Jurado, Manuel 1 ; Fonseca, João E 13 ; Netea, Mihai G 14   VIAFID ORCID Logo  ; Coenen, Marieke J H 15 ; Sainz, Juan 1   VIAFID ORCID Logo 

 Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain; Instituto de Investigación Biosanataria IBs.Granada, Granada, Spain 
 Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain; Instituto de Investigación Biosanataria IBs.Granada, Granada, Spain; Rheumatology department, Virgen de las Nieves University Hospital, Granada, Spain 
 Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain 
 Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands 
 Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 
 Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands 
 Area of Genomic Medicine, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain 
 CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa, Lisbon, Portugal 
 Rheumatology department, Virgen de las Nieves University Hospital, Granada, Spain 
10  Rheumatology Unit, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain 
11  Rheumatology department, Reina Sofía Hospital/IMIBIC/University of Córdoba, Córdoba, Spain 
12  Immunology department, Virgen de las Nieves University Hospital, Granada, Spain 
13  Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHLN, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Center, Lisbon, Portugal 
14  Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany 
15  Department of Human Genetics, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands 
Pages
1-16
Publication year
2019
Publication date
Oct 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2305791579
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.